SHOX2_PTGER4 DNA Methlyation in Lung Cancer

Completed

• Conditions: Lungcancer

• Registration Number: NCT04321499
• Lead Sponsor: University Hospital, Essen

Brief Summary

Data on SHOX2 and PTGER4 DNA Methylation suggest possible use as a biomarker for early lung cancer diagnosis.

In this study a control group consisting of COPD patients with a CT-scan of the chest no older than 6 weeks and a control group of patients with a nodule and ruled out diagnosis of lung cancer will be included.

SHOX2 and PTGER4 will be analyzed via PCR.

Detailed Description

Data on SHOX2 and PTGER4 DNA Methylation suggest possible use as a biomarker for early lung cancer diagnosis.

In this study a control group consisting of COPD patients with a CT-scan of the chest no older than 6 weeks and a control group of patients with a nodule and ruled out diagnosis of lung cancer will be included.

A total of 150 patients will be enrolled in this study. SHOX2 and PTGER4 will be analyzed via PCR of blood plasma samples.

Study Timeline

• Study Start: 2016-05
• Primary Completion: 2017-03
• Study Completion: 2017-03
• Status Verified: 2020-03
• Study First Submitted: 2020-03-23
• Study First Submitted QC: 2020-03-23
• Last Update Submitted: 2020-03-23
• Study First Posted: 2020-03-25
• Last Update Posted: 2020-03-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

suspicious finding for lung cancer on CT-scan

Exclusion Criteria

• history significant for former malignant diseases

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
DNA Methylation at early stages of lung cancer	1 year

Trial Locations

Locations (1)

Ruhrlandklinik, Department of Interventional Pneumology; 🇩🇪 Essen, NRW, Germany